key: cord-0702774-4ch6knqn authors: Whitehead, Bradley; Christiansen, Simon; Østergaard, Lars; Nejsum, Peter title: Helminths and COVID-19 susceptibility, disease progression and vaccination efficacy date: 2022-01-19 journal: Trends Parasitol DOI: 10.1016/j.pt.2022.01.007 sha: a1e7754d22ee26a495dc4569be8828021590fff4 doc_id: 702774 cord_uid: 4ch6knqn Almost two years into the COVID-19 pandemic it remains to be determined how helminths interact with SARS-CoV-2. We discuss how helminths may alter susceptibility to infection, COVID-19 pathology and efficiency of vaccines by combined analysis of available COVID-19 data and previous investigations of the effect of helminths in viral infections. Helminth infections account for 8 of the 20 neglected tropical diseases, many of which are targeted for elimination/eradication by the World Health Organization, yet still infect an estimated 1.5-2 billion people worldwide with many cases concentrated in sub-Saharan Africa (SSA). The COVID-19 pandemic in SSA appears to have progressed with a milder trajectory than predicted and to that observed in Europe and North America. The underlying mechanisms are unknown and are likely multifactorial with contributors including population age, connectivity of population centres, co-morbidity rates and crossreactive immunity to other pathogens. Paradoxically, people of black African origin based in North American or European countries are disproportionately affected by COVID-19. A preliminary study has shown that patients admitted to hospital had a lower risk of developing severe COVID-19 if they were coinfected with parasites, including helminths [1] . This would indicate that helminth induced regulatory Th2 response, with increased TGFβ, IL-10 and expansion of regulatory immune cells is beneficial during COVID-19, likely via attenuation of host hyperimmune activation. Conversely, a Th2 biased immune response may come at the expense of Th1 responses required for viral control and clearance. These mechanisms are not mutually exclusive and almost 2 years into the pandemic 3 crucial questions remain unanswered: 1. Does helminth infection increase susceptibility to SARS-CoV-2 infection? 2. Does helminth infection affect COVID-19 disease progression and patient outcomes? 3. Are SARS-CoV-2 vaccines equally effective in helminth-infected individuals? Assessing whether helminth infection modulates SARS-CoV-2 spread requires an accurate estimation of virus prevalence. Reduced testing capacity can underestimate infection burden and complicates comparisons. Alternatively, population-based seroprevalance surveys can provide an estimation of COVID-19 rates at a given time. Two such surveys undertaken at approximately the same time returned an estimated antibody prevalence of 6% in the UK and 2.1% across 6 Zambian districts [2, 3] . However, J o u r n a l P r e -p r o o f Journal Pre-proof when current infections were included, detected by PCR, the estimated prevalence in Zambia increased to 10.6%, highlighting the impact of timing and testing protocols during an active outbreak. A recent metaanalysis including 15 studies covering 9 sub-Saharan African countries in the period April to October 2020 returned a higher estimated prevalence of 18.76% (13.09-24.42%) compared to 7.29% (6.58-8.01%) in North America and Europe [4] . Immunological surveys are also susceptible to underestimation resulting from seroreversion, which is exacerbated in countries where the majority of cases are mild or asymptomatic due to a correlation between severity of disease and antibody levels. Indeed, 76.2% of infections in Zambia were asymptomatic compared to 32.2% in the UK, suggesting prevalence in SSA may be even higher than estimated [2, 3] . Combined, this suggests that COVID-19 prevalence is not reduced in SSA but that the disease course may be milder. inconclusive to date. Determining causal or direction of effects is difficult in co-prevalence studies, nevertheless, a positive association between Schistosoma haematobium or lymphatic filariasis and HIV infection has been demonstrated [5] . Work in animal models investigating co-infection by helminths and other viruses could be informative for predicting molecular mechanisms in COVID-19 infection (reviewed by Desai et al. 2021[6] ). For example, the rectal infective dose required to establish simian HIV infection was 17 fold lower in S. mansoni co-infected macaques, suggesting that some helminth infections can increase viral susceptibility. In mice, enteric helminth infection with H. polygyrus impaired immunity to murine norovirus infection in a Th2 dependent mechanism. The same helminth reduced the severity of respiratory syncytial virus (RSV) infection, in a Th2 independent but type I interferon and microbiota-dependent mechanism [6] . Chronic and therefore liver restricted, S. mansoni infection reduced susceptibility of mice to lethal challenge with HVPR8 Influenza A virus and increased viral clearance in a model of RSV infection. Whilst, chronic S. mansoni infection resulted in increased replication of hepatotropic LCMV virus [6] . Combined, this indicates detrimental local but beneficial distal effects. However, H. polygyrus infected mice showed increased susceptibility to neurotropic flaviviral challenge with increased viral loads in the J o u r n a l P r e -p r o o f Journal Pre-proof brain, spinal cord, small intestine and colon suggesting both local and remote effects of H. polygyrus infection [6] . Helminth mediated immune modulation can restrict virus levels via IL-4 priming of virtual memory CD8 + T cells resulting in increased virus antigen specific CD8 + T cells upon challenge [6] . Treg cells that are expanded during helminth infection, induce the mobilisation of dendritic cells and CD8 + T cells that can be crucial to early virus control and clearance [7] . These studies highlight the complexity of transkingdom pathogen interactions and suggest that effects are likely helminth and virus specific, Th2 dependent or independent and both local and distal to the helminth infection niche. COVID-19 seroprevalance surveys combined with helminth infection status are required throughout SSA with the region-specific dominance of some helminths perhaps enabling determination of key helminth species in these interactions. Notably, studies in helminth endemic regions outside SSA, such as Amazonas, point to increased severity of COVID-19, however, there are many genetic and environmental factors that may contribute to these observations beyond helminth burden and investigations are urgently required [8, 9] . Severe COVID-19 is characterised by a hyperactive immune response leading to a -cytokine storm‖ and Importantly, the effects of helminths are prolonged with attenuated vaccine responses up to 16 weeks after infection clearance in mice [15] . The propensity for repeat infections and prolonged immune effects suggest that current mass drug administration programs or anthelminthic therapy immediately prior to vaccination may be ineffective. However, two doses of Albendazole administered at day 0 and day 30 prior to vaccination with an attenuated oral cholera vaccine were sufficient to double seroconversion J o u r n a l P r e -p r o o f Journal Pre-proof rates [14] . Therefore, anthelminthics, started sufficiently prior to and maintained up to vaccination, may be beneficial and warrant further investigation to improve outcomes though logistical issues coordinating treatments are significant. Alternatively, an assessment of vaccine efficiency in helminth-infected individuals may provide critical information for selecting optimal vaccines for use in SSA. For example, current COVID-19 mRNA based vaccines Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) lack traditional adjuvants and contain modified nucleosides to increase translation and reduce immunogenicity. This is beneficial in hyper-immune reactive people in the developed world but may be counter-productive in populations with attenuated innate immune responses resulting from helminth infection. Adenoviral vaccines, including Astra-Zeneca (ChAdOx1 nCoV-19) and Johnson & Johnson (JNJ-78436735), may prove more successful due to an inherent ability to activate TLRs, particularly intracellular TLRs and nucleic acid sensors and thereby increase innate responses to develop effective cellular and humoral immunity. We postulate that helminth infection may be beneficial in preventing cytokine storms and severe COVID-19, yet it remains unknown if helminth infection increases susceptibility to COVID-19 infection through impaired viral control. The effects of helminth infection on COVID-19 vaccination programs are yet to be determined, however, previous studies of other vaccines and work in animal models discussed above suggests cause for concern. Effect of co-infection with intestinal parasites on COVID-19 severity: A prospective observational cohort study Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic Update on SARS-CoV-2 seroprevalence: regional and worldwide Schistosoma and Other Relevant Helminth Infections in HIV-Positive Individuals-an Overview Helminth-virus interactions: determinants of coinfection outcomes Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection Chronic Immune Activation and CD4+ T Cell Lymphopenia in Healthy African Individuals: Perspectives for SARS-CoV-2 Vaccine Efficacy Do parasite infections interfere with immunisation? A review and metaanalysis Helminth Infections Suppress the Efficacy of Vaccination against Seasonal Influenza PN was supported by Independent Research Fund Denmark (DFF-6111-00521). BW was supported by Independent Research Fund Denmark (DFF-1032-00242). The authors declare no competing interests.